AI Article Synopsis

  • The study evaluated the impact of rosiglitazone (RSG) on late lumen loss and the progression of nonculprit coronary artery lesions in Type 2 diabetics through a double-blind randomized trial involving 65 participants.
  • The results showed no significant difference in late lumen loss between the RSG and placebo groups, with rates of rapid angiographic progression being similar for both groups.
  • High-sensitivity C-reactive protein levels were found to be a predictor of rapid angiographic progression, but RSG treatment did not effectively reduce plaque progression and had mixed effects on cardiac risk markers.

Article Abstract

Background: Type 2 diabetics (DM2) are at increased risk for restenosis as well as nonculprit coronary artery lesion (NCCL) progression. Rosiglitazone (RSG) favorably modifies many of the altered biologic processes in DM2, although recent reports have questioned its safety. We conducted a double-blind randomized trial to assess the effects of RSG versus placebo on in-stent late lumen loss (LL) and angiographic progression of NCCL.

Methods: A total of 65 DM2 were randomized to RSG (4 mg/d) (n = 32) or placebo (n = 33) at the time of stenting and underwent clinical and laboratory analysis at 1 and 4 months and 8-month angiography (n = 46 patients). Rapid angiographic progression (RAP) was defined as > or =20% diameter reduction of preexisting NCCL by quantitative coronary angiography, or a new narrowing > or =30%.

Results: Mean LL in RSG (n = 33 lesions) was not different from that of placebo (0.62 +/- 0.59 vs 0.70 +/- 0.67, P = NS). Seven (13.5%) of 52 NCCLs have RAP in RSG versus 9 (16.1%) of 56 in placebo (P = NS). High-sensitivity C-reactive protein (hs-CRP) was the only predictor of RAP. Patients with a 120-day hs-CRP > or =75th percentile had an OR of 7.35 (95% CI 2.35-23) for RAP versus those below. Although RSG treatment also lowered log (hs-CRP) at 4 months (RSG 0.10 +/- 0.37 vs placebo 0.26 +/- 0.49, P = .06), it did not decrease the likelihood of plaque progression while also raising LDL and N-terminal brain naturetic peptide.

Conclusions: Rosiglitazone appears not to lower LL or reduce angiographic progression of NCCL in DM2 and had complex effects on markers of cardiac risk.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2008.11.013DOI Listing

Publication Analysis

Top Keywords

angiographic progression
12
in-stent late
8
rsg versus
8
rsg
7
progression
6
placebo
6
predictive factors
4
factors in-stent
4
late loss
4
loss coronary
4

Similar Publications

Background: Growing evidence suggests a potential link between periodontal disease and the development of atherosclerosis, positioning periodontal disease as a possible risk factor for cardiovascular diseases (CVD). This study aimed to evaluate periodontal status in patients with coronary artery disease (CAD) by measuring the Periodontal Inflamed Surface Area (PISA) score in individuals undergoing coronary angiography.

Material And Methods: In this cross-sectional study, 300 patients scheduled for coronary angiography at K.

View Article and Find Full Text PDF

Background: Upfront 2-stent techniques are often used in bifurcation percutaneous coronary interventions (PCI), but there is controversy about optimal strategy selection.

Methods: The authors examined the clinical and angiographic characteristics and long-term outcomes of 232 bifurcation PCIs that were performed using the double kissing (DK) crush or culotte technique in 216 patients between 2014 and 2023 using data from the Prospective Global Registry for the Study of Bifurcation Lesion Interventions (NCT05100992). The inverse probability of treatment weighted (IPTW) Cox proportional hazards model was used to assess long-term outcomes.

View Article and Find Full Text PDF

Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide despite significant improvements in diagnostic modalities. Emerging evidence suggests that erythrocytes, or red blood cells (RBCs), are one of the most important contributors to the events implicated in atherosclerosis, although the molecular mechanisms behind it are under investigation. We used NMR-based lipidomic technology to investigate the RBC lipidome in patients with CHD compared to those with normal coronary arteries (NCAs), all angiographically documented, and its correlation with coronary artery stenosis.

View Article and Find Full Text PDF

Background And Purpose: This animal study was designed to evaluate in vivo the acute and short-term safety and efficacy of the new Artisse intrasaccular device (ISD) for aneurysm occlusion and to gain knowledge about the behavior in the aneurysms.

Materials And Methods: The device was implanted in 7 white New Zealand rabbits with bifurcation aneurysms. Immediate and 90-day angiographic follow-up as well as histologic and scanning electron microscope imaging were evaluated.

View Article and Find Full Text PDF

Background And Objective: Cerebral aneurysms occur as balloon-like outpouchings in an artery, which commonly develop at the weak curved regions and bifurcations. When aneurysms are detected, understanding the risk of rupture is of immense clinical value for better patient management. Towards this, Fluid-Structure Interaction (FSI) studies can improve our understanding of the mechanics behind aneurysm initiation, progression, and rupture.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!